Iovance Q3 net loss $99.6M ($0.63/sh); BLA submission for lifileucel on track to complete in Q4 2022

IOVANCE BIOTHERAPEUTICS, INC.

2022-Q3 EPS reported -$1.85

Cash, equivalents, investments & restricted cash $366.6M at Sep 30, 2022, down from $602.1M at Dec 31, 2021; runway into 2024.
Net loss $99.6M vs $86.1M YoY; R&D expense $72.5M (+$7.1M), G&A $27.9M (+$7.0M).
Rolling BLA for lifileucel in advanced melanoma started August 2022, expected to complete in Q4 2022.
Phase 3 trial of lifileucel + pembrolizumab in frontline advanced melanoma on track to begin late 2022.
iCTC facility annual capacity for 2,000+ patients; new cGMP manufacturing suites for commercial supply.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IOVANCE BIOTHERAPEUTICS, INC. reported the quarter ended September 30, 2022 results: net income $99.6 million, or $0.63 per share, EPS $0.63 per share.

Period: the quarter ended September 30, 2022
Net income: $99.6 million, or $0.63 per share
EPS: $0.63 per share
Result: reported results

Exact text from the filing

Net loss for the third quarter ended September 30, 2022, was $99.6 million, or $0.63 per share, compared to a net loss of $86.1 million, or $0.55 per share, for the third quarter ended September 30, 2021.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-114414

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.